)
Edge28 Aug 2026
Bigger, Sharper, IMAX: A Blockbuster Business
How IMAX turned an unscalable, large-screen format into the center of blockbuster filmmaking through cameras, projection, and remastering technology.
Echo IQ
Echo IQ (EIQ) investor relations material
Echo IQ H2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H2 2026 earnings summary28 Aug, 2026
Executive summary
Achieved significant progress in commercialisation, expanding US hospital pipeline and deploying EchoSolv AS at major institutions like Mount Sinai and Beth Israel Deaconess Medical Center.
Completed independent validation of EchoSolv HF, submitted FDA 510(k) application, and expanded Mayo Clinic partnership for potential distribution.
Entered binding Heads of Agreement with Pro Medicus for up to A$20m investment and US reseller partnership.
Strengthened balance sheet post-year-end with A$110m institutional placement and exclusive data-licensing agreement with Advara HeartCare.
Financial highlights
Reported FY26 net loss of $18.6m, compared to $13.3m loss in FY25.
Operating revenue was $91.6k, down from $101.4k in FY25.
Operating expenses (excluding share-based payments) rose to $13.7m from $8.7m year-over-year.
Cash and cash equivalents at 30 June 2026 were $8.7m.
Net assets decreased to $11.6m from $22.8m at prior year-end.
Outlook and guidance
FY27 priorities include converting US pipeline into enterprise deployments, expanding EchoSolv AS utilisation, progressing Pro Medicus partnership, and preparing for EchoSolv HF commercial launch pending FDA clearance.
Focus on integrating Advara HeartCare dataset, advancing new cardiovascular indications, and expanding US sales and implementation capabilities.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Echo IQ
- AUD 110 million raised, FDA clearance imminent, and rapid commercial growth underway.EIQ
Investor update - Strategic partnerships and $110m funding drive rapid US expansion and AI adoption.EIQQ4 2026 TU
- Mayo Clinic and Mount Sinai deals drive U.S. expansion as FDA clearance and revenue ramp near.EIQInvestor update
- EchoSolv AS achieves rapid US adoption and pipeline growth, with solid cash reserves for expansion.EIQQ3 2026 TU
- Net loss increased to $8.66 million amid key clinical and regulatory milestones for US expansion.EIQH1 2026
- EchoSolv HF clinical validation and FDA submission mark pivotal US market progress; cash at $13.21m.EIQQ2 2026 TU
- AI-driven heart diagnostics poised for major U.S. expansion and revenue inflection in 2026.EIQLife Sciences Virtual Investor Forum 2025
- EchoSolv HF nears FDA submission as US adoption surges and cash reserves remain strong.EIQQ1 2026 TU
- AI platform validated at 99.5% sensitivity, FDA submission imminent, and rapid US market adoption expected.EIQStatus Update
Echo IQ
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage